Literature DB >> 29307858

Biochemical signatures mimicking multiple carboxylase deficiency in children with mutations in MT-ATP6.

Austin A Larson1, Shanti Balasubramaniam2, John Christodoulou3, Lindsay C Burrage4, Ronit Marom4, Brett H Graham4, George A Diaz5, Emma Glamuzina6, Natalie Hauser7, Bryce Heese8, Gabriella Horvath9, Andre Mattman9, Clara van Karnebeek10, S Lane Rutledge11, Amy Williamson5, Lissette Estrella5, Johan K L Van Hove12, James D Weisfeld-Adams12.   

Abstract

Elevations of specific acylcarnitines in blood reflect carboxylase deficiencies, and have utility in newborn screening for life-threatening organic acidemias and other inherited metabolic diseases. In this report, we describe a newly-identified association of biochemical features of multiple carboxylase deficiency in individuals harboring mitochondrial DNA (mtDNA) mutations in MT-ATP6 and in whom organic acidemias and multiple carboxylase deficiencies were excluded. Using retrospective chart review, we identified eleven individuals with abnormally elevated propionylcarnitine (C3) or hydroxyisovalerylcarnitine (C5OH) with mutations in MT-ATP6, most commonly m.8993T>G in high heteroplasmy or homoplasmy. Most patients were ascertained on newborn screening; most had normal enzymatic or molecular genetic testing to exclude biotinidase and holocarboxylase synthetase deficiencies. MT-ATP6 is associated with some cases of Leigh disease; clinical outcomes in our cohort ranged from death from neurodegenerative disease in early childhood to clinically and developmentally normal after several years of follow-up. These cases expand the biochemical phenotype associated with MT-ATP6 mutations, especially m.8993T>G, to include acylcarnitine abnormalities mimicking carboxylase deficiency states. Clinicians should be aware of this association and its implications for newborn screening, and consider mtDNA sequencing in patients exhibiting similar acylcarnitine abnormalities that are biotin-unresponsive and in whom other enzymatic deficiencies have been excluded.
Copyright © 2018 Elsevier B.V. and Mitochondria Research Society. All rights reserved.

Entities:  

Keywords:  Inherited metabolic diseases; Leigh disease; Mitochondrial disease; Newborn screening; Organic acidemias; mtDNA

Mesh:

Substances:

Year:  2018        PMID: 29307858     DOI: 10.1016/j.mito.2018.01.001

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.160


  5 in total

1.  The mitochondrial DNA variant m.9032T > C in MT-ATP6 encoding p.(Leu169Pro) causes a complex mitochondrial neurological syndrome.

Authors:  Kaz M Knight; Emily Shelkowitz; Austin A Larson; David M Mirsky; Yue Wang; Ting Chen; Lee-Jun Wong; Marisa W Friederich; Johan L K Van Hove
Journal:  Mitochondrion       Date:  2020-09-12       Impact factor: 4.160

Review 2.  Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases.

Authors:  Kei Murayama; Masaru Shimura; Zhimei Liu; Yasushi Okazaki; Akira Ohtake
Journal:  J Hum Genet       Date:  2018-11-21       Impact factor: 3.172

3.  Homoplasmy of the m. 8993 T>G variant in a patient without MRI findings of Leigh syndrome, ataxia or retinal abnormalities.

Authors:  Russell P Saneto; Kristina E Patrick; Francisco A Perez
Journal:  Mitochondrion       Date:  2021-04-22       Impact factor: 4.534

4.  The role of the clinician in the multi-omics era: are you ready?

Authors:  Clara D M van Karnebeek; Saskia B Wortmann; Maja Tarailo-Graovac; Mirjam Langeveld; Carlos R Ferreira; Jiddeke M van de Kamp; Carla E Hollak; Wyeth W Wasserman; Hans R Waterham; Ron A Wevers; Tobias B Haack; Ronald J A Wanders; Kym M Boycott
Journal:  J Inherit Metab Dis       Date:  2018-01-23       Impact factor: 4.982

5.  Prospective diagnosis of MT-ATP6-related mitochondrial disease by newborn screening.

Authors:  Ryan H Peretz; Nicholas Ah Mew; Hilary J Vernon; Rebecca D Ganetzky
Journal:  Mol Genet Metab       Date:  2021-06-24       Impact factor: 4.204

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.